Long-term holders of Thermo Fisher Scientific (TMO) and Danaher (DHR) have spent the better part of two years watching a recovery get promised and then deferred. On Wednesday morning, before markets open, both companies deliver results that finally carry enough signal to answer the question clearly: has the multi-year bioprocessing upcycle actually started?
What the Numbers Need to Show
Analysts expect Thermo Fisher to post earnings of $6.40 per share on revenue of $11.95 billion for Q3 2026. The consensus implies solid year-over-year growth: EPS up 10.5% and revenue up 7.3% compared to the year-ago quarter. Management has said it expects to deliver at the upper end of its organic growth range, with orders running ahead of revenue. That last detail matters most. Revenue is a lagging confirmation; orders are the leading signal.
Danaher’s bar is lower but the stakes are arguably higher. Danaher guided to core revenue growth of 2% to 3% year over year for Q3 2026, and the company has also been highlighting underlying growth excluding respiratory testing of about 5% in Q2 2026. Analysts expect earnings of $1.92 per share on revenue of $6.56 billion for the quarter. The bioprocessing division, anchored by Cytiva, is the one line in the segment table that investors will read first.
The Bigger Trend Behind the Numbers
The backdrop for Wednesday’s reports has shifted materially since the start of October. Beijing released a draft proposal last Friday that would place five biomedical technologies under export controls. The draft clarifies that restrictions do not apply to licensing, partnerships, and contract research services involving these technologies. That carve-out matters because Reuters reported that Chinese drug developers struck 81 licensing deals during the first six months of 2026, worth as much as $110 billion. Cross-border pharma R&D money is not retreating. It is reorganizing, and reorganizing around the kind of biologic manufacturing infrastructure that Thermo Fisher and Danaher supply.
Monoclonal antibody production remains robust and is expected to continue growing, driven by new molecules, biosimilars, and increased utilization of existing therapies. Every new approved biologic requires consumables. Every new manufacturing site requires equipment. That is the structural demand floor underneath both companies.
The Investment Case
The story of the past year for Danaher centered on orders arriving faster than shipments. On Danaher’s Q2 2026 earnings call, management discussed that more than $100 million of bioprocessing shipments were pushed out into fiscal 2027, and CEO Rainer Blair said underlying order trends remained strong, with bioprocessing orders growing at a mid-teens rate even as revenue disappointed. The stock fell sharply on that news. Wednesday is where deferred shipments either convert or get pushed further out, and the answer changes the entire thesis for DHR holders.
Thermo Fisher is the cleaner compounding story right now. On Thermo Fisher’s Q2 2026 earnings call, management said pharma and biotech demand has been running at mid-single-digit growth, with bioproduction, clinical research, and the distribution channel all contributing, and that China returned to low single-digit growth in Q2 after a period of weakness. Adjusted operating margin reached 22.8% in Q2, up 90 basis points year over year, with full-year guidance calling for roughly 80 basis points of expansion. Consistency is what TMO sells, and it has delivered it quarter after quarter even as peers stumbled.
Building Wealth Around This Idea
Both names belong in the same portfolio role: durable, widemoat businesses that compound through cycles rather than spike on a single quarter. The appropriate response to Wednesday is not to trade the number. It is to use the order data as a calibration point for a position sized over three to five years.
Investors who want broad exposure without single-stock concentration might consider adding Agilent (A) or Revvity (RVTY) on the same thesis. Both have lagged the recovery cycle and carry more earnings leverage to a bioprocessing upturn. They are not the quality compounders TMO and DHR are, but they amplify the same trend at a lower valuation.
Risks to Monitor
The central risk is timing, not direction. The key watch for Q3 is whether Q2’s customer-driven shipment pushouts reverse in Q3 and Q4, or whether the delay extends further. A second deferral would not disprove the recovery thesis, but it would test the patience of investors who have already waited two years for revenue to catch up with orders.
Beijing’s proposed controls also introduce a tail risk worth monitoring. Even though licensing deals are exempted, the U.S. Treasury Department has been preparing new outbound-investment rules for certain sensitive technologies, and any expansion to include biotech licensing would be a meaningful tightening. A shift in those rules would redirect where biologic R&D capital flows, and both Thermo Fisher and Danaher would feel it in their pharma end markets.
Daily Wealth Takeaway
Order books lead revenue by one to three quarters in capital-intensive industries. When you see equipment orders growing more than 30% year over year, as Danaher reported in Q1 2026, the revenue will follow. The only variable is when. Wednesday’s reports do not resolve the macro. They tell you whether the clock is still running or whether the cycle has stalled again. Long-term investors should be reading for that signal, not the headline EPS number.
